An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cardiff Oncology, Inc. (Nasdaq: CRDF) will report its first quarter 2024 financial results on May 2, 2024, after the close of trading. The company will host a conference call and live webcast to discuss the results and provide a business update.
Cardiff Oncology, Inc. (Nasdaq: CRDF) comunicherà i risultati finanziari del primo trimestre del 2024 il 2 maggio 2024, dopo la chiusura delle contrattazioni. L'azienda organizzerà una conferenza telefonica e una trasmissione web in diretta per discutere i risultati e fornire un aggiornamento sulle attività aziendali.
Cardiff Oncology, Inc. (Nasdaq: CRDF) informará de sus resultados financieros del primer trimestre de 2024 el 2 de mayo de 2024, después del cierre del mercado. La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo para discutir los resultados y proporcionar una actualización sobre el negocio.
Cardiff Oncology, Inc. (나스닥: CRDF)는 2024년 1분기 재무 결과를 2024년 5월 2일 거래 종료 후에 보고할 예정입니다. 회사는 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜과 라이브 웹캐스트를 주최할 것입니다.
Cardiff Oncology, Inc. (Nasdaq : CRDF) annoncera ses résultats financiers pour le premier trimestre 2024 le 2 mai 2024, après la clôture des marchés. La société organisera une conférence téléphonique et une diffusion en direct pour discuter des résultats et fournir une mise à jour sur ses activités.
Cardiff Oncology, Inc. (Nasdaq: CRDF) wird seine Finanzergebnisse für das erste Quartal 2024 am 2. Mai 2024 nach Börsenschluss veröffentlichen. Das Unternehmen wird eine Telefonkonferenz und ein Live-Webcast veranstalten, um die Ergebnisse zu diskutieren und ein Geschäftsupdate zu geben.
Positive
None.
Negative
None.
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT -
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading.
Conference Call and Webcast
Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company's website following the completion of the call.
About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
When will Cardiff Oncology report its first quarter 2024 financial results?
Cardiff Oncology will report its first quarter 2024 financial results on May 2, 2024, after the close of trading.
What is the ticker symbol for Cardiff Oncology?
The ticker symbol for Cardiff Oncology is CRDF.
What time will the conference call and webcast be held on May 2, 2024?
The conference call and webcast will be held at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024.
Where can individuals listen to the live conference call?
Individuals can listen to the live conference call by using the webcast link in the 'Investors' section of the company's website at https://investors.cardiffoncology.com/news-events/events.
Will a replay be available after the conference call?
Yes, a replay will be available in the investor relations section on the company's website following the completion of the call.
trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh
